blog

Palatin Technologies Reports Promising PL9588 Pre-Clinical Data for Glaucoma Palatin Technologies, a biopharmaceutical company specializing in receptor-targeted therapeutics, has recently unveiled encouraging pre-clinical data for its investigational drug, PL9588, as a potential treatment for glaucoma. This breakthrough could mark a significant advancement in ophthalmology, offering new hope for millions of patients suffering from this sight-threatening […]

Palatin’s PL9588 Shows Promising Glaucoma Treatment Data Exciting new developments in glaucoma treatment are emerging as Palatin Technologies reveals promising data for its investigational drug, PL9588. This novel therapy could offer a breakthrough for millions of patients suffering from glaucoma, a leading cause of irreversible blindness worldwide. With glaucoma affecting over 80 million people globally,

Revolutionary Glaucoma Drug Targets Pressure and Nerve Damage in $9.7B Market Glaucoma, a leading cause of irreversible blindness worldwide, has long been a challenge for both patients and medical professionals. Traditional treatments have primarily focused on lowering intraocular pressure (IOP), but a groundbreaking new drug is set to revolutionize the market by addressing both pressure

Palatin’s PL9588 Shows Dual-Action Promise for Glaucoma at ARVO 2025 Exciting advancements in glaucoma treatment were unveiled at the Association for Research in Vision and Ophthalmology (ARVO) 2025 conference, where Palatin Technologies presented promising data on their investigational drug, PL9588. This novel therapy demonstrates a dual-action mechanism targeting both intraocular pressure (IOP) reduction and neuroprotection—a

Glaucoma Market to Hit $13.43 Billion by 2034 with 4.5% CAGR Growth The global glaucoma market is on a steady upward trajectory, projected to reach a staggering $13.43 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.5%. This growth is fueled by rising prevalence of glaucoma, advancements in treatment options, and

Top Eye Specialists in Northern Virginia Protect Your Vision Your vision is one of your most valuable senses, and ensuring its health should be a top priority. In Northern Virginia, a region known for its advanced medical facilities, top eye specialists are dedicated to providing exceptional care to protect and enhance your eyesight. Whether you

# How Fovea-Disc Distance Affects Glaucoma Scan Accuracy Glaucoma is a leading cause of irreversible blindness worldwide, and early detection is crucial for preventing vision loss. One of the key diagnostic tools for glaucoma is **optical coherence tomography (OCT)**, which measures the thickness of the retinal nerve fiber layer (RNFL). However, the accuracy of these

# Sanoculis’ MINT® Glaucoma Treatment Secures CE Mark Approval ## A Breakthrough in Glaucoma Management The medical technology sector has witnessed a significant milestone with **Sanoculis** receiving **CE Mark approval** for its innovative **MINT® Glaucoma Treatment**. This cutting-edge solution promises to revolutionize how glaucoma is managed, offering a minimally invasive approach to reducing intraocular pressure

Transforming Indian Healthcare for a Brighter Future The Indian healthcare system has come a long way, yet challenges persist. With a growing population, increasing healthcare demands, and the need for equitable access, India stands at a critical juncture. Transforming Indian healthcare is not just a necessity—it’s an opportunity to build a healthier, more prosperous nation.

CIME 2025: Community Collaboration Key to Glaucoma Care Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. With millions affected and many unaware of their condition until significant vision loss occurs, the need for early detection and comprehensive care has never been greater. The upcoming CIME 2025 (Community